Ignite Creation Date:
2024-05-06 @ 3:49 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04773756
Status:
COMPLETED
Last Update Posted:
2021-02-26
First Post:
2021-02-22
Brief Title:
Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt
Sponsor:
Alexandria University
Organization:
Alexandria University
Study Overview
Official Title:
Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt Single Center Study
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sofosbuvir has been recently recommended as a possible antiviral for COVID-19 based on structural studies and multiple alignment analysis By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2 it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None